HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival.

AbstractBACKGROUND:
miR-26a plays a critical role in tumorigenesis, either as a tumor suppressor or as an oncogenic miRNA, depending on different tumor types. However, the function of miR-26a in pancreatic cancer has not been clearly elucidated. The present study was designed to determine the roles of miR-26a in pancreatic cancer and its association with the survival of patients with pancreatic cancer.
METHODS:
The expression of miR-26a was examined in 15 pairs of pancreatic duct adenocarcinoma (PDAC) and their adjacent benign pancreatic tissues (ABPT), by qRT-PCR. The results were confirmed by in situ hybridization using two panels of 106 PDACs and their ABPT microarray. The association of miR-26a expression with overall survival was determined. The proliferation and cell cycle distribution of Capan-2, SW-1990, and Panc-1 cells, transfected with miR-26a mimics or a miR-26a inhibitor, were assessed using the Cell Counting Kit-8 assay and flow cytometry, respectively. The cell tumorigenicity was evaluated via murine xenograft experiments. Cyclin D2, E2, EZH2, and PCNA levels were analyzed by Western blot and immunohistochemistry.
RESULTS:
miR-26a was expressed in the cytoplasm of pancreatic ductal epithelial cells, whereas its expression was significantly downregulated in PDAC tissues compared with that of ABPT. Patients with low miR-26a expression had a significantly shorter survival than those with high miR-26a expression. The in vitro and in vivo assays showed that overexpression of miR-26a resulted in cell cycle arrest, inhibited cell proliferation, and decreased tumor growth, which was associated with cyclin E2 downregulation.
CONCLUSIONS:
miR-26a is an important suppressor of pancreatic ductal carcinoma, and can prove to be a novel prognostic factor and therapeutic target for pancreatic cancer treatment.
AuthorsJingjing Deng, Miaoxia He, Lizao Chen, Chao Chen, Jianming Zheng, Zailong Cai
JournalPloS one (PLoS One) Vol. 8 Issue 10 Pg. e76450 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID24116110 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CCNE2 protein, human
  • Cyclins
  • MIRN26A microRNA, human
  • MicroRNAs
Topics
  • Adenocarcinoma (genetics, metabolism, pathology)
  • Animals
  • Blotting, Western
  • Carcinoma, Pancreatic Ductal (genetics, metabolism, pathology)
  • Cell Line, Tumor
  • Cell Proliferation
  • Cyclins (genetics, metabolism)
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization
  • Kaplan-Meier Estimate
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • MicroRNAs (genetics)
  • Middle Aged
  • Pancreatic Neoplasms (genetics, metabolism, pathology)
  • RNA Interference
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tissue Array Analysis
  • Transplantation, Heterologous
  • Tumor Burden (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: